Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptomic analysis from ciprofloxacin treated human triple negative breast cancer cells

ABSTRACT: Transcriptomic analysis from ciprofloxacin treated human triple negative breast cancer cells

PROVIDER: PRJNA566196 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Transcriptomic analysis from ciprofloxacin treated human triple negative breast cancer cells

Project description:A DNA microarray study was conducted to determine the impact of Mt-CFX on mRNA expression and pathway activation in human triple negative breast cancer cells. We used microarrays to detail the global program of gene expression underlying cellularisation and identified distinct classes of up- and down-regulated genes during this process.

2020-03-17 | GSE137679 | GEO

Metastasis in triple-negative breast cancer

Project description:Metastasis in triple-negative breast cancer

| PRJNA437929 | ENA

FOXC1 in triple negative breast cancer

Project description:FOXC1 in triple negative breast cancer

| PRJNA882754 | ENA

Triple therapy reduced metastasis in triple-negative breast cancer.

Project description:Triple therapy reduced metastasis in triple-negative breast cancer.

| PRJNA832953 | ENA

LINC00461 binding protein in triple negative breast cancer

Project description:Using CHIRP-MS method to detect LINC00461 binding protein in MDA-MB-231 cell line of triple negative breast cancer

2023-04-04 | PXD041363 |

High-throughout sequencing of triple negative breast cancer cells treated actived compound D16

Project description:The high-throughput sequencing technology was performed after the treatment of human triple negative breast cancer cells MDA-MB-231 with the active compound D16 designed and synthesized by ourselves, to explore the expression of genes related to cell proliferation, adhesion, migration and invasion of human triple negative breast cancer cells MDA-MB-231 after the treatment of the active compound Changes to explore the effect of active compounds on the proliferation and motility of triple breast breast cancer cells and to find an interesting target gene, CKAP2.

2021-08-17 | GSE182063 | GEO

Triple Negative Breast tumors: SPARC Positive Tumors vs SPARC Negative Tumors

Project description:The aim of this study was evaluate the transcriptome changes in the comparison between triple negative tumors with increased SPARC expression and triple negative tumors with decreased SPARC expression according to Nagai et al., 2011 (Breast Cancer Res Treat (2011) 126:1–14) The results generated could be of particular interest to better define the prognostic impact of SPARC expression in triple negative breast tumors

2018-07-01 | GSE98931 | GEO

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

Project description:This phase I trial is studying the side effects and best dose of giving 7-hydroxystaurosporine together with irinotecan hydrochloride in treating patients with metastatic or unresectable solid tumors, including triple-negative breast cancer (currently enrolling only patients with triple-negative breast cancer since 6/8/2007). Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving 7-hydroxystaurosporine together with irinotecan hydrochloride may help kill more cancer cells by making tumor cells more sensitive to the drug.

| 2007227 | ecrin-mdr-crc

Heterogeneity of triple-negative breast cancer

Project description:Heterogeneity of triple-negative breast cancer was examined and compared across morphologic and molecular features

2018-01-01 | GSE97342 | GEO

Differential analysis of nucleolar proteomics in triple negative breast cancer

Project description:Breast cancer is one of the most common cancers in women. Of the different subtypes of breast cancer, the triple negative breast cancer subtype of breast cancer is the most aggressive. A proteomic screen of nucleolar content across breast cancer subtypes found that triple negative breast cancer cell lines have a distinct nucleolar proteome signature in comparison to non-TNBC breast cancer cell lines.

2021-03-05 | PXD021201 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data